Vulvar Cancer Treatment: A Game-Changer for Women's Health?
Exciting news for women's health in Aotearoa New Zealand! The STRIVE clinical trial, a groundbreaking study aimed at revolutionizing vulvar cancer treatment, is now available locally. But here's where it gets controversial: could less surgery actually be better for certain types of vulvar cancer? And this is the part most people miss: understanding the role of HPV and chronic conditions like lichen sclerosus in shaping treatment outcomes.
Announced by the Australian New Zealand Gynaecological Oncology Group (ANZGOG) in partnership with the Canadian Cancer Trials Group (CCTG), the STRIVE trial (Stratification of Vulvar Squamous Cell Carcinoma by HPV and p53 status to Guide Excision) marks a significant leap forward in personalized surgical care for women with vulvar squamous cell carcinoma (VSCC). This international, prospective study aims to refine surgical decision-making based on tumor biology, potentially reducing complications and improving quality of life.
Why is this important? VSCC, the most common form of vulvar cancer, primarily affects postmenopausal women and arises through two distinct pathways: HPV-associated or HPV-independent. Recent research suggests that HPV-associated cancers may be less aggressive, raising questions about the necessity of extensive surgery. Conversely, HPV-independent cancers, often linked to lichen sclerosus, may require more aggressive treatment due to higher recurrence risks. The STRIVE trial seeks to clarify these differences, offering hope for tailored treatment plans.
Here’s how it works: The study focuses on estimating 3-year local recurrence rates in patients with HPV-associated (HPV-A) and HPV-independent (HPV-I) VSCC, managed surgically based on differentiated vulvar intraepithelial neoplasia (dVIN) and p53 status. By evaluating these factors, researchers aim to:
- Improve risk stratification for surgical management
- Reduce local recurrence rates
- Support evidence-based margin assessment
- Strengthen clinical guidelines for VSCC treatment
- Promote personalized treatment approaches
But here's the catch: While studies suggest less surgery might be safe for HPV-associated cancers, this hasn’t been formally tested. STRIVE aims to fill this gap, potentially leading to fewer complications and better functional outcomes. For HPV-independent cancers, the presence of p53 abnormalities and dVIN at the tissue edge may indicate a higher recurrence risk, necessitating more aggressive treatment. The trial’s findings could reshape how we approach these two distinct cancer types.
What does this mean for patients? Early-stage HPV-associated cancers might require no additional treatment after initial surgery, while HPV-independent cases may benefit from more extensive procedures. The goal is to minimize side effects without compromising outcomes. With vulvar cancer being relatively rare, international collaboration through STRIVE is crucial to gathering robust evidence.
Key Details:
- Eligibility: Adult women with primary VSCC, FIGO stage I–II.
- Study Launch: Opened in Canada on October 1, 2024, with 8 international sites and 13 participants enrolled to date. The first Australasian site at Auckland City Hospital launched on January 30, 2026, led by Dr. Lois Eva.
- Registration: ClinicalTrials.gov (NCT06358469) and ANZCTR (link available upon request).
Thought-Provoking Question: Should treatment for vulvar cancer be standardized, or is personalized care based on HPV status and molecular markers the future? Share your thoughts in the comments!
For more information, visit: STRIVE Trial Video or ANZGOG Website.
About ANZGOG: The Australia New Zealand Gynaecological Oncology Group is dedicated to improving outcomes for individuals affected by gynaecological cancers through clinical trials and multidisciplinary research. Contact Monique Cerreto at [email protected] or +61 0416 282 464 for media inquiries.
